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Background
The germline mutations in BRCA1/2 genes are the most
significant and well characterized genetic risk factors for
breast and/or ovarian cancer. Detection of mutations in
these genes is an effective method of cancer prevention
and early detection. Different ethnic and geographical
regions may have different BRCA1 and BRCA2 mutation
spectrum and prevalence due to founder effect. The
population of Lithuania has over several centuries under-
gone limited mixing with surrounding populations and is
mostly of indigenous Baltic origin, which is different
from Slavs. The aim of our study was to asses full
BRCA1/2 mutational profile in Lithuanian population.
Methods
We performed comprehensive mutation analysis of
BRCA1/2 genes in 605 unrelated breast and/or ovarian
cancer patients (with/without family history) and predictive
unaffected patients (with family history) using high resolu-
tion melting (HRM) screening (Light Cycler 480/Light
Scanner 384) followed by direct sequencing (ABI 3500)
and MLPA for large genomic rearrangements (LGRs).
Results
Overall, we have identified 25 different mutations (16
in BRCA1 and 9 in BRCA2 genes). Seven frequent pathoge-
nious mutations in BRCA1 gene (c. 4035delA, c.5266dupC,
c.181T>G, c.1687C>T, c.5258G>C, c.3700_3704del5,
c.4789C>G, del 1-3ex) comprised 48%, 29%, 7,7%, 3,5%,
2,1%, 1,4% and 1,4% respectively of all BRCA1 mutations; a
single BRCA2 mutation (c.658delGT) comprised 43% of all
mutations in this gene. Five novel BRCA1 (c.4516delG,
c.2481delA, c.5560delC, del 16-19ex, del 3-12ex) and 4
novel BRCA2 genes mutations (c.6408_6414del7,
c.5701_5714del14, c.6410delA, c.6999insT) were identified;
3 different LGRs (del 1-3ex, del 16-19ex, del 3-12ex) were
found in BRCA1. The most common c.4035delA (48% of
all BRCA1/2 mutations) appears to be true Lithuanian
(Baltic) founder mutation and haplotype data confirmed
ancient origin of this mutation c.a. 62 generations ago.
Conclusions
Characterization of BRCA1/2 mutational profile in
Lithuania enabled to develop screening protocol using
HRM for 8 common BRCA1/2 point mutations, which
comprise 88% of all mutations detected in our country.
This knowledge will provide more efficient approach for
the individualization of genetic testing affordable for all
breast/ovarian patients and their relatives.
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